Feist, Eugen http://orcid.org/0000-0002-9872-5282
Baraliakos, Xenofon http://orcid.org/0000-0002-9475-9362
Behrens, Frank http://orcid.org/0000-0001-8750-7186
Thaçi, Diamant http://orcid.org/0000-0001-8513-550X
Plenske, Anja
Klaus, Pascal
Meng, Thomas
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
https://doi.org/10.1007/s40744-021-00418-5
Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE
https://doi.org/10.1007/s40744-023-00633-2
Funding for this research was provided by:
Pfizer Pharma GmbH
Article History
Received: 2 August 2023
Accepted: 15 December 2023
First Online: 3 February 2024
Declarations
:
: Eugen Feist received consulting/speaker fees from AbbVie, BMS, Celgene, Galapagos, Lilly, Medac, Novartis, Pfizer, Roche, Sanofi, Sobi, and UCB. Xenofon Baraliakos received honoraria or grants from AbbVie, Amgen, Biocad, BMS, Celltrion, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, and UCB. Frank Behrens received research grants from Bionorica, Celgene, Chugai, Janssen, Pfizer, and Roche; and consulting/speaker fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Chugai, Janssen, Genzyme, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB. Diamant Thaçi was consultant, investigator, and speaker, and has participated in advisory boards for AbbVie, Almirall, Amgen, Biogen Idec, BMS, Celgene, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Regeneron, Sanofi, and UCB; and has received research/educational grants from AbbVie, Leo-Pharma Celgene Corp, and Novartis. Anja Plenske, Pascal Klaus, and Thomas Meng are employees and shareholders of Pfizer.
: This non-interventional study was conducted in accordance with the Declaration of Helsinki and is registered with the Federal Institute for Drugs and Medical Devices, the Federal Association of Statutory Health Insurance Physicians, and the Head Association of Health Insurers. Written informed consent was obtained by the treating physician or a designated person prior to patients entering the study. The final protocol and subject information and informed consent documentation were reviewed and approved by the Ethics Committee of the Faculty of Medicine of the Goethe University of Frankfurt am Main, Germany (432/14).